Livercancer | People

Scientific Vita

Contact

Info

Prof. Dr.

Thomas Longerich

Project: B08

Academic Education and Scientific Degrees

2011

Postdoctoral Lecture Qualification (Habilitation)

2003

MD-Thesis, Institute of Pathology, University of Cologne (magna cum laude; supervised by Prof. Dr. P. Schirmacher)

1995-2002

Study of Medicine, University of Cologne

Professional Career

Since 2018

Deputy Director, Institute of Pathology, University of Heidelberg

Since 2017

Professor of General Pathology and Head of Division Translational Gastrointestinal Pathology, Institute of Pathology, University of Heidelberg

2016-2017

Executive Senior Physician, Deputy Head, Institute of Pathology, University Hospital RWTH Aachen

2015-2017

Head NGS Diagnostics, Institute of Pathology and Deputy Head, Center for NGS Diagnostics, University Hospital RWTH Aachen

2014-2017

Professor of Oncological Pathology, Institute of Pathology, University Hospital RWTH Aachen

2012-2014

Consultant Pathologist, Institute of Pathology, University of Heidelberg

2010-2012

Consultant Pathologist for Hepatopathology, Institute of Pathology, University of Heidelberg

2009

Board Certification in Pathology

Since 2007

Research group leader

Address: Institute of Pathology
University Hospital Heidelberg
Im Neuenheimer Feld 224
69120 Heidelberg
Phone: +49/6221/56 4188
eMail: thomas.longerich@med.uni-heidelberg.de

Awards and appointments

2019

Research Award, German Society of Pathology

Since 2018

Scientific Secretary and Treasurer, German Association for the Study of the Liver (GASL)

2017

Professor of General Pathology, Institute of Pathology, University of Heidelberg

2015-2019

Coordinator of the Working Group Molecular High-Throughput Diagnostics, German Society for Digestive and Metabolic Diseases

2014

Distinguished Clinical Study 2014 “Efficacy and Non-Target Effects of TACE in Bridging of HCC Patients to Liver Transplantation - a Histopathological Study”; Journal of Vascular and Interventional Radiology

2014

Virchow Price, German Society of Pathology

Since 2013

Member of the Laennec Liver Pathology Society

2011

Poster award, 27th Annual Meeting of the German Association for the Study of Liver disease (GASL), Regensburg

Publications

Longerich T, Endris V, Neumann O, Rempel E, Kirchner M, Abadi Z, Uhrig S, Kriegsmann M, Weiss KH, Breuhahn K, Mehrabi A, Weber TF, Wilkens L, Straub BK, Rosenwald A, Schulze F, Brors B, Froehling S, Pellegrino R, Budczies J, Schirmacher P, Stenzinger A. RSPO2 gene rearrangement: a powerful driver of β-catenin activation in liver tumours. Gut 2019;68:1287-1296.

Seehawer M, Heinzmann F, D´Artista L, Harbig J, Roux PF, Hoenicke L, Dang H, Klotz S, Robinson L, Doré G, Rozenblum N, Kang TW, Chawla R, Buch T, Vucur M, Roth M, Zuber J, Luedde T, Sipos B, Longerich T, Heikenwälder M, Wang XW, Bischof O, Zender L. Necroptosis microenvironment directs lineage commitment in liver cancer. Nature 2018;562:69-75.

Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, Agdashian D, Terabe M, Berzofsky JA, Fako V, Ritz T, Longerich T, Theriot CM, McCulloch JA, Roy S, Yuan W, Thovarai V, Sen SK, Ruchirawat M, Korangy F, Wang XW, Trinchieri G, Greten TF. Gut microbriome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 2018;360:eaan5931.

Mueller C, Waldburger N, Stampfl U, Kauczor HU, Schirmacher P, Sommer CM, Longerich T. Non-invasive diagnosis of hepatocellular carcinoma revisited. Gut 2018;67:991-993.

Mueller S, Nahon P, Rausch V, Peccerella T, Silva I, Yagmur E, Straub BK, Lackner C, Seitz HK, Rufat P, Sutton A, Bantel H, Longerich T. Caspase-cleaved keratin-18 fragments increase during alcohol withdrawal and predict liver-related death in patients with alcoholic liver disease. Hepatology 2017;66:96-107.

Endig J, Buitrago-Molina LE, Marhenke S, Reisinger F, Saborowski A, Schutt J, Limbourg F, Konecke C, Schreder A, Michael A, Misslitz AC, Healy ME, Geffers R, Clavel T, Haller D, Unger K, Finegold M, Weber A, Manns MP, Longerich T, Heikenwalder M, Vogel A. Dual Role of the Adaptive Immune System in Liver Injury and Hepatocellular Carcinoma Development. Cancer Cell 2016;30:308-323.

Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang TW, Hohmeyer A, Pesic M, Leibold J, von Thun A, Schirmacher P, Zuber J, Weiss KH, Powers S, Malek NP, Eilers M, Sipos B, Lowe SW, Geffers R, Laufer S, Zender L. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med 2014;20:1138-1146.

Tschaharganeh DF, Xue W, Calvisi DF, Evert M, Michurina TV, Dow LE, Banito A, Katz SF, Kastenhuber ER, Weissmueller S, Huang CH, Lechel A, Andersen JB, Capper D, Zender L, Longerich T, Enikolopov G, Lowe SW. p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell 2014;158:579-592.

Pellegrino R, Calvisi DF, Neumann O, Kolluru V, Wesely J, Chen X, Wang C, Wuestefeld T, Ladu S, Elgohary N, Bermejo JL, Radlwimmer B, Zörnig M, Zender L, Dombrowski F, Evert M, Schirmacher P, Longerich T. EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma. Hepatology 2014;59:1886-1899.

Neumann O, Kesselmeier M, Geffers R, Pellegrino R, Radlwimmer B, Hoffmann K, Ehemann V, Schemmer P, Schirmacher P, Lorenzo Bermejo J, Longerich T. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. Hepatology 2012;56:1817-1827.

Publications